– USA, NY – K Health, the 24/7 primary care system, today announced the appointment of Vivian Riefberg to its board of directors.
Vivian Riefberg is a board member at Johns Hopkins Medicine, PBS, and Signify Health (NYSE: SGFY) and the former co-leader of the health services practice at McKinsey & Company.
“We’re thrilled for Vivian to bring a unique and fresh perspective to our board,” said CEO and co-founder, Allon Bloch. “She’s joining a passionate group of similar-minded people who, like everyone at K, are dedicated to changing how we all approach healthcare.”
K Health also announced that Chen Yehudai, former VP and General Counsel at Teva Pharmaceuticals (NYSE: TEVA), has joined its executive team as the first General Counsel.
With over 4 million users, K Health’s base continues to grow, with demand increasing rapidly since the start of the pandemic. Riefberg and Yehudai will help scale and develop the product in anticipation of continued growth.
About Vivian Riefberg
Vivian Riefberg brings over 30 years of experience in the global healthcare industry to the K Health board of directors. As a Senior Partner and former board member at McKinsey & Company, she co-led the firm’s health services practice, led the public sector practice, and spent more than three decades serving clients across the healthcare ecosystem. She is a Professor of Practice at the University of Virginia Darden School of Business and a Director Emeritus at McKinsey & Company.
“K Health has the potential to reduce annual medical costs by billions of dollars through its approach to tackling the biggest healthcare issues,” said Vivian Riefberg. “With partnerships involving the largest players in the industry, I am honored to join a company that is working towards providing affordable, convenient, and quality care to millions of people, especially as we navigate through the COVID-19 pandemic and beyond.”
About Chen Yehudai
Chen Yehudai joins K Health as its first General Counsel. In this role, Yehudai will lead K Health’s legal and compliance functions. She previously spent more than 13 years at Teva Pharmaceuticals, where she was the Vice President and General Counsel of Global Antitrust and Global HR and Corporate Affairs. Before Teva, she was an Associate at Skadden, Arps, Slate, Meaghar & Flom in New York City. She holds an LL.M. and a doctoral degree from Columbia University School of Law.
Last month, K Health announced the formation of Hydrogen Health, a joint venture with Anthem and Blackstone to advance high-quality digital and affordable healthcare. In January 2021, K Health announced K Pediatrics, an offering with insights and care for children aged 3-17 that’s free with a K Health membership. K Health has also partnered with Baltimore City Public Schools, Boost Mobile, and Louisiana State University to make 24/7 access to doctors a reality for everyone in the U.S.
About K Health
K Health, headquartered in New York, is the digital healthcare company on a mission to use the power of shared knowledge to get everyone access to better, affordable healthcare—whenever, wherever they need it. K Health is a free tool that uses AI to help people understand how doctors diagnose and treat those with similar symptoms and conditions. Its data-driven platform consolidates the knowledge of thousands of doctors and billions of clinical data insights to get people trusted information and treatment. K Health also offers the option to chat with a clinician without insurance for less than a copay. K Health treats almost all primary care conditions, as well as anxiety and depression, and offers customizable treatment plans and prescriptions.
Frequently the #1 downloaded app in the App Store’s medical category, K Health is available in all 50 states and has helped over 4 million people get access to higher quality and affordable care.
For more information: https://khealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
